U.S. License Holder:
Date of License:
ARCALYST (rilonacept) is an interleukin-1 blocker indicated for:
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older;
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more;
Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older.